Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novo’s Insulin Degludec Faces Advisory Cmte. Scrutiny On Hypoglycemic Benefit, CV Safety

This article was originally published in The Pink Sheet Daily

Executive Summary

In briefing documents for the Nov. 8 panel review, FDA suggests the clinical trial data do not support Novo Nordisk’s assertion of a hypoglycemia advantage with its new long-acting insulin. Agency also raises concerns about a meta-analysis suggesting an increased cardiovascular risk.


Related Content

Novo Nordisk Dismayed By “Complete Response” Letter For Insulin Degludec
Novo Nordisk Dismayed By “Complete Response” Letter For Insulin Degludec
Degludec Review Could Lead To New CV Safety Requirements For Insulins
Insulin Degludec’s CV Risks Can Be Studied Post-Approval, Cmte. Says
Degludec Advisory Committee Is Another De Facto Delay For Novo
New Long-Acting Insulin Offerings Could Derail Lantus Franchise
Novo Highlights Degludec's Advantage Versus Lantus In Fewer Night-Time Hypoglycemic Events


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts